KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.
Advanced HCC|Other Solid Tumors
DRUG: KD6001|DRUG: Tislelizumab|DRUG: Bevacizumab
Number of Participants with Dose Limiting Toxicities (DLTs), DLTs will be assessed during the dose-escalation phase and are defined as the following treatment-related adverse events occurring within a total of 21 days after the first trial administration., Up to Day 21|The incidence and safety profile of participants with adverse events (AEs), serious adverse events(SAE), and immune-related adverse event(irAE), Evaluate the adverse events (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 (NCI CTCAE 5.0)., Baseline to study completion up to 2 years
The antitumor activity of KD6001 in combination with Tislelizumab ± Bevacizumab measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria., Baseline to study completion up to 2 years|Maximum Plasma Concentration [Cmax], The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab., Baseline to study completion up to 2 years|Time to reach maximum serum concentration (Tmax), The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab., Baseline to study completion up to 2 years|Half-life (T1/2), The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab., Baseline to study completion up to 2 years|Area under blood concentration-time curve(AUC0-T and AUC0-∞), The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab., Baseline to study completion up to 2 years|Apparent volume of distribution (Vd), The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab., Baseline to study completion up to 2 years|The immunogenicity of KD6001 in combination with Tislelizumab ± Bevacizumab, Including the incidence of ADA positive. For ADA positive patients, the incidence of neutralizing antibody (Nab) will be analyzed., Baseline to study completion up to 2 years
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.